Gilteritinib Fumarate
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Gilteritinib Fumarate |
| DrugBank ID | DB12141 |
| Brand Names (EU) | Xospata |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.45% |
Approved Indication (EMA)
Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | acute myeloid leukemia with t(8;21)(q22;q22) translocation | 99.45% | DL |
| 2 | acute myeloid leukemia with CEBPA somatic mutations | 99.43% | DL |
| 3 | acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) | 99.39% | DL |
| 4 | acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor | 99.30% | DL |
| 5 | bulbar polio | 99.10% | DL |
| 6 | acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent | 98.99% | DL |
| 7 | acute myeloid leukemia and myelodysplastic syndromes related to radiation | 98.99% | DL |
| 8 | 5q35 microduplication syndrome | 98.89% | DL |
| 9 | myeloid leukemia | 98.58% | DL |
| 10 | therapy related acute myeloid leukemia and myelodysplastic syndrome | 98.54% | DL |
| 11 | acute myeloid leukemia with t(8;16)(p11;p13) translocation | 98.46% | DL |
| 12 | acute myeloid leukemia with t(9;11)(p22;q23) | 98.27% | DL |
| 13 | unclassified acute myeloid leukemia | 98.20% | DL |
| 14 | acute myeloblastic leukemia with maturation | 98.19% | DL |
| 15 | acute myeloblastic leukemia without maturation | 98.11% | DL |
| 16 | acute myeloid leukemia with t(6;9)(p23;q34) | 98.10% | DL |
| 17 | neuralgic amyotrophy | 98.10% | DL |
| 18 | acute myeloid leukemia with minimal differentiation | 98.09% | DL |
| 19 | amyotrophic neuralgia | 97.96% | DL |
| 20 | inherited acute myeloid leukemia | 97.86% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.